Introduction
============

The incidence of colorectal cancer has continued to increase in South Korea. Between 1999 and 2010, the annual percentage change in the age-standardized incidence rate was 5.9% in both sexes. Colorectal cancer has become the second most common cancer among men and third most common cancer among women \[[@b1-roj-2016-01746]\]. Local recurrence is a major factor that influences prognosis of rectal cancer patients, occurring in 10%--15% of patients according to recent studies \[[@b2-roj-2016-01746]\]. Preoperative concurrent chemoradiotherapy (CCRT) demonstrated higher local control and reduced toxicity compared to postoperative CCRT in recent studies \[[@b3-roj-2016-01746]\]. Currently, preoperative CCRT is considered the treatment of choice in locally advanced (T3-4 or node positive) rectal cancer. Downstaging following neoadjuvant radiation shows a favorable survival outcome \[[@b4-roj-2016-01746],[@b5-roj-2016-01746]\]. Also, tumor regression grade (TRG) is considered as an independent prognostic factor for rectal cancer \[[@b6-roj-2016-01746]\]. Fokas et al. \[[@b7-roj-2016-01746]\] suggested that higher TRG correlates with better disease-free survival and lower distant metastasis.

Higher radiation dose is responsible for increase in rectal tumor response and improved sphincter preservation \[[@b8-roj-2016-01746]\]. However, in clinical situation, various factors negatively affect the conformality of radiation delivery. Teh et al. \[[@b9-roj-2016-01746]\] reported that the radiation dose at the air-tissue interface of the rectum, dilated with a rectal balloon, is lower in comparison to the same phantom without an air cavity. When we prepare for delivery of neoadjuvant CCRT in rectal cancer patients, some of the planning computed tomographies (CTs) have large rectal air volume inside the target volumes. If we suppose that large air volume in the rectum persists while delivering radiotherapy (RT), we can presume that the target volume of the rectal wall may be under-dosed, thus affecting the response rate of the tumor.

Our hypothesis in the present study was as follows. A large rectal volume on planning CT for RT may lead to insufficient dose coverage at the rectal wall region, thus negatively affecting the TRG of rectal cancer. This study was intended to confirm the necessity of routine rectal volume evaluation and emptying during neoadjuvant CCRT of rectal cancer patients.

Materials and Methods
=====================

1. Patient population
---------------------

From January to December 2012, among 138 patients who were treated with surgery following neoadjuvant CCRT for rectal cancer at Samsung Medical Center, 113 patients were included in this study. Patients with previous chemotherapy history or previous radiation history, patients who did not complete chemoradiation, and patients whose radiation record not available were excluded from the analysis. The clinical stage of rectal cancer was evaluated by rectum magnetic resonance imaging (MRI), based on the American Joint Committee on Cancer criteria (6th edition). Patients with distant metastasis were excluded from the study.

2. Treatment characteristics
----------------------------

All patients underwent simulation and treatment in the prone position and were scanned with CT for RT planning. All patients received 44 Gy to primary tumor and pelvic nodes in fractional dose of 2 Gy. In cases which surgical resection for lateral pelvic node was not considered feasible, an additional boost dose of 10--16 Gy with reduced field was delivered for 25 patients (22%). Three-dimensional conformal RT plans routinely consisted of two lateral beams with 10-MV photons and one posterior beam with 4-MV photon.

Chemotherapy was delivered in two modalities. Fifty-four patients (48%) were continuously injected with 5-fluorouracil (5-FU) (400 mg/m^2^/day) and leucovorin (20 mg/m^2^/day) during the first week and last week of radiotherapy. One cycle of chemotherapy consisted of 3 days of treatment in a neoadjuvant setting. An alternative regimen of capecitabine (850 mg/m^2^/twice a day) for 35 days during radiotherapy was prescribed for the other 59 patients (52%).

Following neoadjuvant CCRT with an interval of 2 to 3 months, 97 (86%) had low anterior resection, 6 (5%) had abdominal perineal resection, 7 (7%) had intersphincteric resection, and 3 (3%) had local excision.

3. Tumor regression grade
-------------------------

The pathologic response after CCRT was determined by one pathologist for all patients. Pathologic grading of primary tumor regression was performed by determining the amount of fibrotic tissue compared to viable tumor, separated into five groups of TRG, according to Dworak et al. \[[@b10-roj-2016-01746]\]. The five groups of TRG were as follows: grade 4, total regression (no viable tumor cells; only fibrotic mass); grade 3, good regression (dominant fibrosis outgrowing tumor mass, \>50% tumor regression); grade 2, moderate regression (dominant tumor mass with obvious fibrosis in 26%--50% of tumor mass); grade 1, minor regression (dominant tumor mass with obvious fibrosis ≤25% of tumor mass); grade 0, no regression (fibrosis completely absent).

Tumor downstaging was also evaluated, comparing pre-treatment clinical stage and pathologic stage.

4. Assessment of rectal volume
------------------------------

Rectal volume was calculated as summation of all gas volume in axial images containing gross tumor volume (GTV), and was automatically contoured on the axial images of planning CT using the auto-contouring function of the pinnacle planning system (Pinnacle, ver. 9.10; Philips Medical Systems, Andover, MA, USA). [Fig. 1](#f1-roj-2016-01746){ref-type="fig"} shows two examples of planning CT with distended rectum, contoured with GTV, clinical target volume (CTV) and rectal volume.

Average axial rectal area (ARA) was calculated as rectal volume divided by longitudinal tumor length. Longitudinal tumor length was defined as perpendicular distance between upper and lower boundaries of GTV in axial CT images.

The trend of rectal volume change throughout the treatment was assessed for 29 patients whose mid-treatment planning CT was obtainable. Mid-treatment CT images were acquired after receiving 18--22 fraction of radiation, with identical treatment set-up to the primary CT images. Rectal volume evaluation of mid-treatment CT images was performed with the same technique used for primary CT images. We compared two CT images of each patient to evaluate the consistency of rectal volume.

5. Statistical analysis
-----------------------

Paired t-test and Pearson correlation were used to confirm the consistency of rectal volume. Kruskal-Wallis test and student t-test were used to compare rectal volume between different TRG groups. The linear relationship between rectal volume and pathologic response (including TRG and downstaging) was analyzed using Spearman correlation. Clinicopathologic factors in each TRG group was compared with Pearson chi-square test and Kruskal-Wallis test.

All tests were two-sided and considered statistically significant for p-value less than 0.05. We used IBM SPSS ver. 20.0 (IBM, Armonk, NY, USA) for the analysis.

Results
=======

1. Patient characteristics
--------------------------

The patient group had a total of 113 people: 77 male (68%) and 36 female (32%). The median age of the population was 59 years (range, 30 to 81 years). Clinical stage before CCRT was stage I in 5 patients (4%), stage II in 5 patients (4%), and stage III in 103 patients (91%) ([Table 1](#t1-roj-2016-01746){ref-type="table"}).

2. Consistency of rectal volume
-------------------------------

Among 113 patients, we were able to assess mid-treatment planning CT for 29 patients (24%). The average value and 95% confidence interval (CI) of rectal volume was 14.7 mL (95% CI, 9.01 to 20.4 mL) for the primary images and 10.1 mL (95% CI, 4.61 to 15.6 mL) for the mid-treatment images. Paired t-test showed no difference of rectal volume between the two groups (p = 0.147). Also, a linear correlation was found between rectal volumes before and after the treatment (Pearson correlation coefficient = 0.43, p = 0.022), suggesting that the tendency of rectal volume would persist throughout the course of RT.

3. Tumor response and rectal volume
-----------------------------------

Pre-treatment clinical stage and pathologic stage was compared for 113 patients. In this study, 99 patients (88%) showed downstaging and 14 patients (12%) showed no stage reduction. Three cases (3%) showed progression: stage I to II in one case and stage II to IIIA in two cases ([Table 2](#t2-roj-2016-01746){ref-type="table"}).

After the completion of neoadjuvant CCRT, pathologic results showed total regression (TRG 4) in 28 patients (25%), good regression (TRG 3) in 25 patients (22%), moderate regression (TRG 2) in 34 patients (30%), minor regression (TRG 1) in 24 patients (21%), and no regression (TRG 0) in 2 patients (2%).

Average rectal volume and ARA measured on planning CT were 11.1 mL (range, 0 to 65.0 mL) and 2.9 cm^2^ (range, 0 to 19.8 cm^2^), respectively. Proximal tumors (anal verge ≥ 5cm) had larger rectal volume than distal tumors (anal verge \< 5 cm) (mean value: distal 8.6 mL, proximal 14.5 mL; p = 0.034). However, no correlation existed between rectal volume and pre-treatment stage (p = 0.155) or GTV volume (p = 0.161).

Average rectal volumes of each TRG group were 9.0 mL (TRG 4), 8.8 mL (TRG 3), 13.7 mL (TRG 2), 11.7 mL (TRG 1), and 19.2 mL (TRG 0). A borderline difference of rectal volume was found between 5 TRG groups (p = 0.091 by Kruskal-Wallis test). No significant difference between TRG groups was found for ARA (p = 0.126 by Kruskal-Wallis test) ([Table 3](#t3-roj-2016-01746){ref-type="table"}).

A linear correlation was found between TRG and rectal volume (Spearman correlation efficient = --0.20, p = 0.036), but not between downstaging and rectal volume (p = 0.231). Only marginal relationship was found between TRG and ARA (Spearman correlation efficient = --0.18, p = 0.058). To confirm the clinical impact of large rectal volume, we divided the patients into two groups at the median value of rectal volume (large volume group, \>4.3 mL; small volume group, ≤4.3 mL). The large volume group had smaller TRG value (2.31; 95% CI, 2.02 to 2.60) compared to small volume group (2.62; 95% CI, 2.33 to 2.91). However, the difference was not statistically significant (p = 0.145 by t-test). We used the Receiver Operating Characteristic curve analysis to determine the optimal cut-off point for estimating TRG value. As a result, rectal volume of 0.15 mL had the highest sum of sensitivity (0.817) and specificity (0.491). We selected this value as a second cutoff point for further analysis. The group containing larger rectal gas within the rectum (rectal volume ≥0.15 mL, n = 37) had smaller TRG value (2.25; 95% CI, 2.00 to 2.50) compared to the group that had almost none of the gas (2.92; 95% CI, 2.57 to 3.27), with statistical significance (p = 0.003 by t-test). Also, when comparing complete response (TRG 4) with other TRG groups (TRG 0-3), the group containing no rectal gas (rectal volume \< 0.15 mL) also showed more complete response rate with statistical significance (p = 0.040 by t-test).

Subgroup analysis regarding clinical stage and distance from anal verge yielded no significant findings.

4. Group comparison based on TRG
--------------------------------

Based on TRG, clinicopathologic factors of patients were analyzed ([Table 3](#t3-roj-2016-01746){ref-type="table"}). Pre-CCRT stage (p = 0.015), lymphovascular invasion (p = 0.002), and perineural invasion (p \< 0.001) were significantly correlated with TRG. However, distance from anal verge, radiation to surgery interval, and total irradiated dose had no correlation with TRG.

Discussion and Conclusion
=========================

The benefits of preoperative radiotherapy, especially 5-FU-based chemoradiation, have been clearly established in patients with locally advanced rectal cancer \[[@b11-roj-2016-01746],[@b12-roj-2016-01746]\]. Tumor response rate and pathologic downstaging are prognostic factors of rectal cancer, affecting local tumor control and survival rates \[[@b13-roj-2016-01746],[@b14-roj-2016-01746]\]. For rectal cancer, significant dose-response relationship is demonstrated in radiation dose up to 70 Gy, showing that adequate dose delivery is critical for tumor control \[[@b15-roj-2016-01746]\]. Thus, approaches to achieve sufficient dose coverage to the tumor are meaningful, such as in the current study, in which we focused on the impact of large rectal gas volume on tumor control. It have been reported that rectal distention has a significant impact on treatment failure in prostate cancer \[[@b16-roj-2016-01746]\]. Furthermore, many efforts have been made to reduce the variations of rectal volume in prostate cancer, such as laxatives, daily direct gas removal, or diet protocols \[[@b17-roj-2016-01746]-[@b19-roj-2016-01746]\]. Target dislocation is the main issue in the case of prostate cancer; nevertheless, we can presume that large rectal air volume may increase the variation in rectal dose-volume parameters in rectal cancer cases as well.

Dose perturbation near the air-tissue surfaces is one of the main difficulties in delivering RT precisely. Perturbation of the electron fluence occurs in this region of electronic disequilibrium \[[@b20-roj-2016-01746]\]. This concern has been emphasized in head-and-neck tumors due to presence of an air cavity \[[@b21-roj-2016-01746],[@b22-roj-2016-01746]\]. Dose perturbation near the air cavity is strongly dependent on X-ray energy, field size, depth, and size of cavity. For example, the Monte Carlo calculations show dose reductions of 40% and 19% at 0.05 and 2 mm, respectively, beyond the air-water interface for a 3-cm diameter cylindrical air tube irradiated by a single 5 cm × 5 cm 15-MV beam. These reductions became roughly half for parallel-opposed beam arrangement, being 21% and 11% for the same depths \[[@b20-roj-2016-01746]\]. However, in an *in vivo* setting, there are some factors that decrease this dose perturbation. Intra-fractional variation in the internal geometry can result in the statistical averaging of dose distribution. Also, the posterior beam used in this study, which is perpendicular to lateral beams, will decrease the dose reduction effect near the air-tissue surface. The wedges used in the lateral beams may also contribute to diminishing the effects of dose reduction.

In this study, we measured the rectal volume of axial images containing GTV, to investigate the effect of dose perturbation to tumor control in clinical setting. We confirmed that rectal gas volume does not change significantly over fractions of radiation treatment, by reviewing mid-treatment planning CT of 29 patients.

From the analysis of 113 patients who received neoadjuvant CCRT for rectal cancer, we found out that rectal volume in planning CT was not correlated with tumor regression grade. Patients with large rectal volume resulted in lower average TRG value, but there was no statistical significance. We did found a difference of TRG between groups divided at cut-off value of 0.15 mL in rectal volume in this study. However, we are reluctant to correlate this finding towards clinical significance, because the cut-off value is too close to zero, which makes it problematic to have statistical significance. Also, we expected that the dose reduction effect will have clinical impact at larger rectal volumes, but the small value of 0.15 mL does not fit in with the radiophysics basis assumed in this study.

Accordingly, our result does not support that reducing rectal volume before each treatment fraction would be beneficial for patients with large rectal volume. The dose reduction effect from air cavity may not be significant enough to affect the clinical outcomes of the patients. Also, there was no difference of TRG between distant and proximal tumors. Rectal movement in rectal cancer patients mainly occurs in upper rectum, especially in anterior and lateral directions \[[@b23-roj-2016-01746]\]. Although proximal tumors had larger rectal volumes in our study, this anatomic variation throughout the treatment seems to contribute in diminishing the dose reduction effect.

While undergoing neoadjuvant CCRT, total irradiated dose was between 44 Gy to 60 Gy. All boost radiation for 25 patients who received more than 44 Gy was targeting at lateral pelvic nodes, and was planned to minimize additional dose to the rectum. Thus, the only dose scheme irradiated to the main mass was 44 Gy, making it difficult to analyze the dose-response relationship in this patient group.

The main limitation of this study is that inter-fractional images were not acquirable in majority of the patients. We made effort to show the consistency of rectal volume by analyzing the mid-treatment rectal volume in 29 patients, but its statistical power would not be strong enough to be applied for the population group. Ki et al. \[[@b17-roj-2016-01746]\] obtained daily megavoltage CT images in 40 prostate cancer patients while receiving radical RT, and demonstrated that there was no significant variation of rectal volume during the course of RT. Likewise, if there were data of periodic CT images during treatment, we could assess the consistency of rectal volume more precisely. Furthermore, patient group with persistent large rectal volume can be selected to analyze the correlation with tumor response. Therefore, we suggest further studies with sufficient and periodic image data to confirm our results.
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![An example of axial view (A) and sagittal view (B) of planning computed tomography images showing large rectal volume. Each image was contoured with gross tumor volume (orange), clinical target volume (turquoise), and rectal volume (purple). Rectal volume was defined as summation of all gas volume in axial images containing gross tumor volume. GTV, gross tumor volume; CTV, clinical target volume.](roj-2016-01746f1){#f1-roj-2016-01746}

###### 

Patient characteristics

  Characteristic                                                            No. (%)
  ------------------------------------------------------------------------- ------------
  Age (yr), median (range)                                                  59 (30-81)
  Sex                                                                       
   Male                                                                     77 (68.1)
   Female                                                                   36 (31.9)
  Distance from the anal verge (cm)                                         
   \<5                                                                      65 (57.5)
   ≥5                                                                       48 (42.5)
  Clinical tumor staging^[a)](#tfn1-roj-2016-01746){ref-type="table-fn"}^   
   I                                                                        5 (4.4)
   II                                                                       5 (4.4)
   IIIA                                                                     8 (7.1)
   IIIB                                                                     38 (33.6)
   IIIC                                                                     57 (50.4)
  Total dose (Gy)                                                           
   44                                                                       88 (72.7)
   54-60                                                                    25 (22.1)

American Joint Committee on Cancer 6th edition.

###### 

Comparison between pre-treatment stage and postoperative pathologic stage

  Clinical stage^[a)](#tfn2-roj-2016-01746){ref-type="table-fn"}^   Postoperative pathologic stage^[a)](#tfn2-roj-2016-01746){ref-type="table-fn"}^                                                                                                                            
  ----------------------------------------------------------------- --------------------------------------------------------------------------------- ---- ---------------------------------------------------- ---------------------------------------------------- ---- ---- -----
  I                                                                 4                                                                                 \-   1^[b)](#tfn3-roj-2016-01746){ref-type="table-fn"}^   \-                                                   \-   \-   5
  II                                                                3                                                                                 \-   \-                                                   2^[b)](#tfn3-roj-2016-01746){ref-type="table-fn"}^   \-   \-   5
  IIIA                                                              4                                                                                 3    \-                                                   1                                                    \-   \-   8
  IIIB                                                              9                                                                                 13   7                                                    3                                                    6    \-   38
  IIIC                                                              12                                                                                19   12                                                   3                                                    7    4    57
  Total                                                             32                                                                                35   20                                                   9                                                    13   4    113

American Joint Committee on Cancer 6th edition.

Three cases showed progression; stage I to II in one case and stage II to IIIA in two cases.

###### 

Correlation between TRG and clinicopathologic factors

  Characteristic                           TRG0 (n = 2)   TRG1 (n = 24)   TRG2 (n = 34)   TRG3 (n = 25)   TRG4 (n = 28)   p-value
  ---------------------------------------- -------------- --------------- --------------- --------------- --------------- ---------
  Age (yr), median                         58.5           53              59.5            60              59.5            0.406
  Sex                                                                                                                     0.434
   Male                                    2              18              25              14              18              
   Female                                  0              6               9               11              10              
  Tumor site                                                                                                              0.467
   \>Anal verge 5 cm                       2              7               14              12              11              
   ≤Anal verge 5 cm                        0              17              20              13              17              
  Pre-CCRT CEA (ng/mL)                     3.3            4.5             3.2             5.7             3.8             0.435
  Pre-CCRT stage                                                                                                          0.015
   I                                       0              0               1               0               4               
   II                                      0              0               2               0               3               
   IIIA                                    0              2               2               3               1               
   IIIB                                    0              8               13              10              7               
   IIIC                                    2              14              16              12              13              
  CCRT-to-surgery interval (mo), average   128            101             98              89              92              0.239
  Lymphovascular invasion                  1              10              5               4               0               0.002
  Perineural invasion                      0              11              3                               0               \<0.001
  Total dose (Gy)                                                                                                         0.982
   44                                      2              18              27              19              22              
   54-60                                   0              6               7               6               6               
  Rectal volume (mL), average              19.2           11.7            13.7            8.8             9.0             0.091
  ARA (cm^2^), average                     2.9            2.7             3.9             2.4             2.3             0.126

TRG, tumor regression grade; CCRT, concurrent chemoradiotherapy; CEA, carcinoembryonic antigen; ARA, average axial rectal area.
